Article
Pharmacology & Pharmacy
Si-Chun Gu, Qing Ye, Chang-De Wang, Shao-Rong Zhao, Jie Zhou, Chen Gao, Yu Zhang, Zhen-Guo Liu, Can-Xing Yuan
Summary: Pingchan granule (PCG) has a long-lasting and extensive symptomatic efficacy for both motor and non-motor symptoms of Parkinson's disease (PD) with good tolerance.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Frank C. Church
Summary: Parkinson's disease is a progressive neurodegenerative disorder that mainly affects older adults. Treatment options include rehabilitation, therapy, restorative programs, maintenance with complementary and alternative medicine, and surgery as a last resort. Currently, there is no cure for PD and the focus is on slowing disease progression and improving quality of life for patients.
Article
Geriatrics & Gerontology
Kyum-Yil Kwon, Eun Ji Lee, Mina Lee, Hyunjin Ju, Kayeong Im
Summary: The study aimed to compare the non-motor and fall-related features between tremor-dominant (TD) and postural instability-gait difficulty (PIGD) subtypes in early Parkinson's disease (PD) patients. The results showed that in early PD, PIGD subtype is significantly associated with higher levels of fatigue, gastrointestinal dysfunction, and fall-related features compared to the TD subtype.
GERIATRICS & GERONTOLOGY INTERNATIONAL
(2021)
Article
Medicine, General & Internal
Diego Santos-Garcia, Ariadna Laguna, Jorge Hernandez-Vara, Teresa de Deus Fonticoba, Carlos Cores Bartolome, Maria J. Feal Painceiras, Maria Cristina Iniguez-Alvarado, Iago Garcia Diaz, Silvia Jesus, Maria Teresa Boungiorno, Lluis Planellas, Marina Cosgaya, Juan Garcia Caldentey, Nuria Caballol, Ines Legarda, Iria Cabo, Lydia Lopez Manzanares, Isabel Gonzalez Aramburu, Maria A. Avila Rivera, Victor Gomez Mayordomo, Victor Nogueira, Victor Puente, Julio Dotor Garcia-Soto, Carmen Borrue, Berta Solano Vila, Maria Alvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Francisco Carrillo Padilla, Juan C. Martinez Castrillo, Pilar Sanchez Alonso, Maria G. Alonso G. Losada, Nuria Lopez Ariztegui, Itziar Gaston, Jaime Kulisevsky, Manuel Menendez Gonzalez, Manuel Seijo, Javier Ruiz Martinez, Caridad Valero, Monica Kurtis, Jessica Gonzalez Ardura, Ruben Alonso Redondo, Carlos Ordas, Luis M. Lopez M. Diaz, Darrian McAfee, Pablo Martinez-Martin, Pablo Mir
Summary: This study analyzed sex difference manifestations in Spanish patients with Parkinson's disease (PD) and found important differences. Symptoms such as depression, fatigue, and pain were more frequent and/or severe in females, while symptoms such as hypomimia, speech problems, rigidity, and hypersexuality were more noted in males. Women received a lower levodopa equivalent daily dose and had worse perception of quality of life. After two years of follow-up, the NMS burden increased more significantly in males, while the functional capacity was more impaired in females.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Geriatrics & Gerontology
Qu Yi, Yu-Peng Chen, Jiang-Ting Li, Jing-Yi Li, Qi-Xiong Qin, Dan-Lei Wang, Jing-Wei Zhao, Zhi-Juan Mao, Yong-Jie Xiong, Min Zhe, Xue Zheng
Summary: Poor sleep is associated with more severe symptoms in Parkinson's disease (PD), and both insufficient and excessive time spent in bed and nocturnal sleep duration are correlated with higher non-motor symptom burdens. Non-motor symptoms play a mediating role in sleep quality, quality of life, PD severity, and motor symptoms.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Review
Neurosciences
Xiao-Zhong Jing, Xiang-Zhen Yuan, Xingguang Luo, Shu-Yun Zhang, Xiao-Ping Wang
Summary: Nondopaminergic neurotransmitters play a role in Parkinson's disease (PD) and their receptors are potential targets for developing new treatments. This review summarizes the recent findings on nondopaminergic treatments for PD, including drugs to reduce motor complications and improve non-motor symptoms. Several drugs have been approved for managing motor fluctuations and levodopa-induced dyskinesia, while ongoing research is focused on serotonergic and glutamatergic agents. Nondopaminergic drugs also show promise in treating non-motor symptoms such as hallucinations and delusions, daytime sleepiness, depression, and urinary tract symptoms.
CURRENT NEUROPHARMACOLOGY
(2023)
Review
Geriatrics & Gerontology
Li-Li Wang, Cai-Jie Sun, Yan Wang, Ting-Ting Zhan, Juan Yuan, Cong-Ying Niu, Jie Yang, Shan Huang, Ling Cheng
Summary: Dance therapy has a significant effect on improving cognitive function in Parkinson's disease (PD), but it does not show significant improvements in depression, fatigue, and apathy.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2022)
Article
Clinical Neurology
Mariana Fernandes, Mariangela Pierantozzi, Alessandro Stefani, Carlo Cattaneo, Erminio A. Bonizzoni, Rocco Cerroni, Nicola Biagio Mercuri, Claudio Liguori
Summary: This study found a high prevalence of NMS in PD patients with motor fluctuations, with psychiatric disorders being more frequent in older patients and those with a longer PD diagnosis duration, while sleep problems were more common in younger patients with a shorter disease duration.
FRONTIERS IN NEUROLOGY
(2021)
Article
Multidisciplinary Sciences
Ali S. Shalash, Eman Hamid, Hanan Elrassas, Eshak Bahbah, Alia H. Mansour, Hadeer Mohamed, Mahmoud Elbalkimy
Summary: This study aimed to compare non-motor symptoms among patients with essential tremor (ET), Parkinson's disease (PD) subtypes, and healthy controls. The results showed that both PD patients and ET patients exhibited more severe non-motor symptoms and depression compared to controls. Identifying different non-motor symptoms profiles is crucial for predicting, assessing, and managing ET and PD subtypes.
Article
Multidisciplinary Sciences
Kyum-Yil Kwon, Suyeon Park, Eun Ji Lee, Mina Lee, Hyunjin Ju
Summary: The study revealed that fall-related risk factors in patients with early Parkinson's disease (PD) were highly associated with gastrointestinal dysautonomia.
SCIENTIFIC REPORTS
(2021)
Article
Geriatrics & Gerontology
Kaixin Dou, Jiangnan Ma, Xue Zhang, Wanda Shi, Mingzhu Tao, Anmu Xie
Summary: This study aimed to develop clinical risk models using non-motor predictors to distinguish between early Parkinson's disease (PD) and healthy individuals. In addition, prognostic models were constructed to predict the progression of non-motor symptoms in de novo PD patients at a 5-year follow-up.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Article
Clinical Neurology
Meimei Zhang, Yawen Gan, Xuemei Wang, Zhan Wang, Tao Feng, Yumei Zhang
Summary: This study investigated the correlation between non-motor symptoms and dual-task gait performance in patients with Parkinson's disease (PD). The results showed that dual-task gait performance can reflect the burden of non-motor symptoms in early-stage PD, and gait cycle duration is a valuable parameter for further research and management of PD.
NEUROLOGICAL SCIENCES
(2023)
Review
Clinical Neurology
David Nascimento
Summary: Drooling in Parkinson's disease is a complex issue that involves multiple clinical features and is not caused by a single factor. Some factors contribute to the onset of drooling while others are associated with it.
NEUROLOGICAL SCIENCES
(2021)
Article
Neurosciences
Marina Picillo, David-Erick Lafontant, Susan Bressman, Chelsea Caspell-Garcia, Christopher Coffey, Hyunkeun Ryan Cho, Elliot L. Burghardt, Nabila Dahodwala, Rachel Saunders-Pullman, Caroline M. Tanner, Amy W. Amara
Summary: Men with early untreated Parkinson's disease (PD) showed greater longitudinal changes in motor and non-motor features compared to women. They also required higher dopaminergic medication dosages over time. However, there were no sex-related progression patterns observed in biological biomarkers.
JOURNAL OF PARKINSONS DISEASE
(2022)
Review
Neurosciences
Xiao-Zhong Jing, Hui-Jia Yang, Reyisha Taximaimaiti, Xiao-Ping Wang
Summary: Dopamine (DA) agonists are excellent dopamine replacement therapy for Parkinson's disease (PD) patients and are crucial in controlling motor and non-motor symptoms. Each DA agonist has unique characteristics, efficacy, and safety profile. Understanding DA agonists helps clinicians balance clinical efficacy and side effects.
CURRENT NEUROPHARMACOLOGY
(2023)